India is set to accept the Serum Institute of India's (SII) request for a Rs 3,000-crore ($400 million) grant to boost its capacity to make the AstraZeneca COVID-19 vaccine, a government source with knowledge of the matter told Reuters.
SII, the world's biggest vaccine maker, sought the funds to increase its monthly capacity to more than 100 million doses by the end of May, from up to 70 million currently.
The country has administered more than 112 million doses of the shot so far, the highest in the world, despite concerns about some people overseas developing blood clots after receiving the vaccine.
The Indian government is in fact struggling to meet demand for the drug from many states as infections spread rapidly.
"We are clear that we will give whatever support is necessary to develop and boost the availability of vaccines in the country," the source said on Sunday, declining to be identified as he was not authorised to speak publicly on the matter.
A finance ministry spokesman declined to comment. SII, which will soon also start making the Novavax COVID-19 vaccine, did not respond to a request for comment.
India has so far injected 123 million vaccine doses, including nearly 11 million of a domestically developed shot known as Covaxin.
The government is also trying to boost output of Covaxin and has also changed rules to fast-track imports of vaccines developed by Pfizer, Moderna and Johnson and Johnson.
($1 = 74.8600 Indian rupees)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU